Inhibikase Therapeutics, Inc.
USD1.96
+0.03 (+1.30%)
CEO
Mark T. Iwicki
IPO Date
2020-12-23
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Country
US
Open
$1.93
Prev. Close
$1.93
Day Low
$1.92
Day High
$1.96
52W Low
$1.33
52W High
$2.26
Market Cap
$0.26B
Volume
0.62M
| 338,282 |
| $0.00 |
| 24 Feb 2026 | Munshi Amit | director | D-Return | Disposed | 19,089 | $0.00 |
| 7 Jan 2026 | Iwicki Mark T | director, officer: Chief Executive Officer | A-Award | Acquired | 4,982,706 | $2.01 |
| 7 Jan 2026 | Cabell Christopher | President & Head of R&D | A-Award | Acquired | 900,117 | $2.01 |
| 7 Jan 2026 | McIntyre David | Chief Financial Officer | A-Award | Acquired | 986,319 | $2.01 |
| 24 Nov 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10 percent owner | P-Purchase | Acquired | 2,068,965 | $1.45 |
| 28 Aug 2025 | Cabell Christopher | President & Head of R&D | Disposed | 0 | $0.00 |
| 28 Aug 2025 | Aurentz Vincent | director | Disposed | 0 | $0.00 |
| 28 Aug 2025 | Munshi Amit | director | A-Award | Acquired | 57,265 | $0.00 |